Argitalpenak (90) Araceli Alonso Cánovas argitalpenak

2024

  1. Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice

    Neurologia, Vol. 39, Núm. 4, pp. 340-344

  2. Exercise Habits in People with Parkinson's: A Multinational Survey

    Movement Disorders Clinical Practice

  3. Levodopa inhalada: de la evidencia a la experiencia

    Revista de neurologia, Vol. 78, Núm. S01, pp. S1-S10

  4. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

  5. Revisiting the jumping to conclusions bias in functional movement disorders

    Journal of Neurology, Neurosurgery and Psychiatry

2023

  1. Clinical Features of Idiopathic Normal Pressure Hydrocephalus: Critical Review of Objective Findings

    Movement Disorders Clinical Practice, Vol. 10, Núm. 1, pp. 9-16

  2. Cognitive impairment and dementia in young onset Parkinson’s disease

    Journal of Neurology, Vol. 270, Núm. 12, pp. 5793-5812

  3. Functional movement disorder comorbidity in Parkinson's disease: A multicenter descriptive study

    Parkinsonism and Related Disorders

  4. Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: A national multicentre observational study

    Journal of Neurology, Neurosurgery and Psychiatry

  5. Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review

    Brain Sciences, Vol. 13, Núm. 2

  6. The Early Treatment Phase in Parkinson's Disease: Not a Honeymoon for All, Not a Honeymoon at All?

    Journal of Parkinson's disease, Vol. 13, Núm. 3, pp. 323-328

  7. ¿Qué piensan los estudiantes de Medicina sobre los trastornos neurológicos funcionales?

    Revista de neurologia, Vol. 76, Núm. 8, pp. 265-271

2022

  1. Efficacy and safety of high doses of safinamide in advanced Parkinson disease

    Parkinsonism and Related Disorders

  2. Eye-of-the-Tiger Sign with an Unexpected Pathological Diagnosis

    Movement Disorders Clinical Practice, Vol. 9, Núm. 1, pp. 98-103

  3. The silver linings of Parkinson’s disease

    npj Parkinson's Disease

2021

  1. Apomorphine: A powerful ally in parkinson's disease

    Revista de Neurologia, Vol. 72, Núm. 9, pp. 323-332

  2. COVID-19 in Parkinson’s disease: what holds the key?

    Journal of Neurology, Vol. 268, Núm. 8, pp. 2666-2670

  3. Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review

    Movement Disorders Clinical Practice, Vol. 8, Núm. 1, pp. 25-32

  4. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 4, pp. 761-769

  5. Impact of SAfinamide on depressive symptoms in parkinson’s disease patients (SADness-PD Study): A multicenter retrospective study

    Brain Sciences, Vol. 11, Núm. 2, pp. 1-11